Logo image
Patient-derived forebrain cortical organoids reveal biphasic tau-MAP6-microtubule axis dysfunction in tauopathy
Journal article   Open access   Peer reviewed

Patient-derived forebrain cortical organoids reveal biphasic tau-MAP6-microtubule axis dysfunction in tauopathy

Xiaohuan Sun, Skandha Ramakrishnan, Victor C Ogbolu, Nicholas M Kanaan, Celeste M Karch, Peter W Baas and Liang Qiang
Alzheimer's & dementia, v 22(7), e71565
Jul 2026
PMID: 42411568
url
https://pmc.ncbi.nlm.nih.gov/articles/PMC13338887/View
Open
url
https://doi.org/10.1002/alz.71565View
Published, Version of Record (VoR) Open

Abstract

Humans Induced Pluripotent Stem Cells - metabolism Microtubule-Associated Proteins - metabolism Microtubules - metabolism Microtubules - pathology Neurons - metabolism Neurons - pathology Organoids - metabolism Organoids - pathology Prosencephalon - metabolism Prosencephalon - pathology tau Proteins - genetics tau Proteins - metabolism Tauopathies - genetics Tauopathies - metabolism Tauopathies - pathology
In frontotemporal dementia (FTD), tau detaches from axonal microtubules and forms pathological aggregates. Rather than stabilizing microtubules, tau promotes labile microtubule domains, redefining its role in neurodegeneration and underscoring the need for human models that capture temporal disease progression. Human induced pluripotent stem cells carrying MAPT , MAPT , or MAPT mutations and isogenic controls were differentiated into forebrain cortical organoids (1 to 8 months). Tau isoforms, microtubule dynamics, MAP6 regulation, neuronal activity, tau mRNA stability, and tau pathology were analyzed using biochemical, imaging, and electrophysiological approaches, some of which were benchmarked to postmortem behavorial variant FTD cortex. Early-phase tau mutant organoids showed elevated tau, hyperdynamic microtubules, and neuronal hyperexcitability, partially reversible by tau reduction. Late-phase organoids exhibited insoluble tau accumulation, microtubule hyperstability, and neurodegeneration and reactive astrocytes, accompanied by opposing, phase-dependent MAP6 changes. This work reveals a biphasic tau-MAP6-microtubule mechanism driving tauopathy and establishes these organoids as a platform for phase-specific therapy.

Details

UN Sustainable Development Goals (SDGs)

This publication has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

Source: SDGs in the Output

InCites Highlights

Data related to this publication, from InCites Benchmarking & Analytics tool:

Collaboration types
Domestic collaboration
Web of Science research areas
Clinical Neurology
Logo image